Background: The inhibition of both hydrolysis products of acetylcholine (ACh), Acetylcholinesterase (AChE) and Butyrylcholinesterase (BChE), is essential for successful treatment of Alzhemier patients. Objectives: This study was investigated inhibition potentials of recently synthesized disubstituted tacrines derivatives on going our research against AChE, BChE and carbonic anhydrase cyctosolic (hCA I and II) enzymes to explore the Structure activity relationship (SAR). Methods: Inhibitory activities of tested compounds against AChE and BChE were measured by spectrophotometric method, developed by Ellman et al. Furthermore, the disubstituted tacrines were determined as inhibitors of two physiologically relevant CA isoforms, the cytosolic hCA I and II by an esterase assay method. Results: The silyl, thiomethyl and cyano substituted seven membered hydrocycle tacrines (9, 11 and 14) significantly inhibited AChE, compared with starting compound 3 (6,8-dibromo-2,3,4,5-teytrahydro-1H-cyclohepta[1,2-b] quinoline) and reference compounds, galantamine and tacrine, while methoxy substituted seven membered hydrocycle tacrine derivative 10 showed selective inhibition against BChE (IC 50 = 563 nM). Interestingly, disubstituted tacrines displayed higher or parallel inhibition to galantamine. Additionally, all these tacrine analogues were recorded to be powerful inhibitor compounds of the cytosolic isoenzyme hCA I with K i in the range of 43.81-471.67 nM, as well as a moderate selectivity toward hCA II isoenzyme with K i in the range from 87.14 to 614.68 nM compared with AZA, as standard. Conclusion: The disubstituted seven membered hydrocycle tacrine analogues 9-12 and 14 may have promising anti Alzhemier drug candidate and dibromo six membered hydrocycle 2 and dibromo seven membered hydrocycle 3 derivatives may be novel hCA I and II enzyme inhibitors.
INTRODUCTION
Alzheimer's disease (AD) is characterized as a neurological disorder and considered as lack of cognitive abilities in the elderly people. 1 AD starts with loss of memory accompanied by an increase of AChE activity that leads to run out of cholinergic and noncholinergic neurons in the brain.
Amyloid beta-protein plaques which form in the brain, are degradation product of Cholinesterase enzyme (ChE). 2 There are several suggestions to the treatment of AD. The most preferred medication is discovery of either new cholinesterase inhibitors (alternative to donepezil, rivastigmine, tacrine and galanthamine) or N-methyl-D aspartate (NMDA) receptor antagonists such as memantine. 3 Adverse effects of some synthetic acetylcholinesterase inhibitors used for the treatment of AD such as tacrine and donepezil, leads to reseachers to find innocent and most potent derivatives of these drugs. [4] [5] Therefore, it is very important to find new substances, more efficient and less expensive than the currently used drugs. Tacrine was the first AChE inhibitor to be launched and approved by FDA as an AD drug. 6 However, it exhibited several adverse effects which in some cases led to several problems. 7 Due to that, many other AChE inhibitors have been studied and researchers have still continued to improve the pharmacological profile of the novel drug candidate. 1, 8 There are restricted reports about the synthesis of substituted tacrine displayed AChE inhibitory activity. Some reported studies showed halogenated tacrine analogues have better inhibitory activity compared with unsubstituted one. 1 In a work, the high inhibition of a set of 6-and 7-substituted with Cl and F atoms 9-amino-1,2,3,4-tetrahydroacridine-1-ols were determined. 9 In a theoretical work, it was concluded that Cl atom at C-6 of tacrine increased the binding strength to AChE probably due to its electron withdrawing effect. 10 Carbonic anhydrase (CA, E.C.4.2.1.1) enzymes significantly exist in red blood cells and gastrointestinal tract of vertebrates and are class of zinc enzymes which perform catalyzing the reversible hydration of CO 2 into protons and HCO 3 -under physiological situations 11 and exist in blood pH homeostasis and play a key role in CO 2 transport to the lung cells. 12, 13 CA inhibitors (CAIs) have recently been common studying area due to their significant applications for the treatment and prevention of an extensive number of diseases. The inhibition and activation effects of CA by many chemicals and drugs have been reported in the literature.
14 At least 16 CA isoforms were defined up to present in mammals, the scads active ones as catalyst agents for CO 2 hydration being CA II and IX. 15, 16 Additionally, the realization of the physiological outcomes of inhibiting particular CA isoforms is developing as the science base about subcellular positions building CA enzymes kinetics, expression levels and tissue repartition. Most of these isoforms have shown promise as medication aims with CAs now involved in regions where human treatments are extremely needed, for example, obesity-specific (CA V) pathways, in cancer-specific (CA IX and XII) and in brain function (CA XIV). [16] [17] Our group recently reported the preparation of novel disubstituted tacrine derivatives, including five, six and seven membered hydrocycles, 18 through cyclodehydration reaction of several ketones and 2-amino-3,5-dibromobenzonitrile via Friedlander reaction furnished a series of dibromo tacrines. Then, bromo tacrine analogues were converted to corresponding disubstituted tacrine analogues by metal catalyzed or metal halogen exchange. The present work is a continuation of our ongoing research. 18 Due to having the AChE inhibition potential of the tricyclic structure of the 1,2,3,4-tetrahydroacridine nucleus, we focused on investigation of anticholinergic activities of recently reported disubstituted tacrine as potential AChE, BChE, hCA I and hCA II inhibitors. Furthermore, to fill the gap in the SAR of substituted tacrine we focused on our work on tricyclic tacrine based AChE, BChE, hCA I and II inhibitors [19] [20] by testing a series of disubstituted tacrine analogues. The IC 50 values for the inhibition of AChE and BChE were studied by means of SAR approach, in search for describing the dependence of AChE, BChE, hCA I and hCA II inhibitory activity on substituents of tacrine cycles.
MATERIALS AND METHODS

Chemistry
The synthesis of dibromo (1-5) tacrines via Friedländer reactions and disubstituted (7) (8) (9) (10) (11) (12) (13) (14) tacrine derivatives via metal assisted electrophilic and nucleophilic substituted reactions and MeI salt form (6) of unsubstituted tacrine were reported recently by our previous publications. 18, 21 The isolated compounds (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) were fully characterized with melting point, HRMS analysis, infrared, 1 H, 13 C, HMBC and HETCOR spectroscopy in this paper.
18
This study was carried out with disubstituted tacrine derivatives (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) according to our previous paper. 18, 21, 22 Anticholinesterase Activity Assays
The inhibitory efficacy of disubstituted tacrine derivatives (1-14) on BChE/AChE activities was obtained conforming to the spectrophotometric Ellman's procedure. 23 Butrylcholine iodide (BChI) and also acetylthiocholine iodide (AChI) compounds were used as substrates of the both reactions. 24 In this part, 5,5′-dithio-bis(2-nitrobenzoic)acid (DTNB) was used for the estimation of the BChE/AChE activities. 24 Briefly, 130 µL of buffer solution (pH 8.0, Tris/HCl, 100 mM) and diverse concentration of sample solutions (50-200 µL) dissolved in deionised water were added to 50 µL of BChE/ AChE solutions. Then, the mixture was incubated for 15 min at 25°C. Finally, 50 µL of DTNB (0.5 mM and 25 mL) of BChI/AChI was added to incubated mixture. Also, the reaction was initiated by the addition of 50 µL of BChI/AChI. The activities of these enzymes were evaluated spectrophotometrically at a wavelength of 412 nm. 25 The butyrylcholinesterase enzyme obtained from Equus caballus and acetylcholinesterase enzyme isolated from Electrophorus electricus were obtained from market. Galantamine and Tacrine compounds were used as control compound. Ethanol was used as a solvent to dissolve test compounds and the controls. The anticholinesterase activity of the fourteen tacrine derivatives were measured at different concentrations (10 -8 -200 µM) for calculation of the IC 50 values. Each substance was tested three times in triplicate against AChE and BChE enzymes. The percentage of inhibition of AChE or BChE was determined by a comparison of the rates of reaction of samples relative to blank sample (ethanol in phosphate buffer pH 8) using the formula;
where E is the activity of enzyme without test sample and S is the activity of enzyme with test sample.
Carbonic anhydrase I and II isoenzymes purification and inhibition studies
The purification of both cytosolic CA isoforms (hCA I and II) of human blood cells was previously explained with a simple one-step procedure by a Sepharose-4B-LTyrosine-sulphanilamide affinity chromatography as described previously. 26 The protein quantity in the column effluents was evaluated spectrophotometrically at 280 nm previously described. For purification of both isoenzymes, sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was applied. CA isoenzymes activities were obtained in conforming to Verpoorte procedure 27 explained previously in details. 28 Increasing absorbance of the reaction medium was spectrophotometrically obtained at 348 nm. We utilized the esterase activity procedure for ascertaining the inhibition agents by the Lineweaver-Burk procedure. 29 CA activity (%) versus inhibitory concentration and 1/V versus 1/[S] graphs were drawn. The quantity of protein was determined at 595 nm according to Bradford's procedure. 30 Bovine serum albumin was used as standard protein. 31 For the designation of the inhibition efficacy of each novel disubstituted tacrine derivatives on both hCA isoenzymes, an activity (%)-[disubstituted tacrine derivatives] graph was drawn. The IC 50 values were obtained from activity (%) versus compounds plots. For the calculation of K i values, disubstituted tacrine derivatives concentrations were used.
RESULTS
Chemistry
In our previous papers, 18, [21] [22] one-pot synthesis was described for bromo tacrine derivatives (1-5) (Figure 1) using Friedländer reactions of several cyclic ketones and brominated 2-amino-3,5-dibromobenzonitrile (17) in the presence of some Lewis acids. To achieve the direct bromination, tacrine was treated to methyl iodine to protect of the N atom in the cycle. This reaction furnished the methyl iodine salt form (6) of unsubstituted tacrine. Tacrine bromides were converted corresponding thiomethyl (13) (14) and silyl (11) (12) derivatives by the treatment of dibromo 1 and 2 derivatives with n-BuLi followed by trapping with an electrophile [Si (Me) 3 Cl, S 2 (Me) 2 ] (Scheme 1). Copper-assisted nucleophilic substitution reactions of brominated tacrines furnished cyano (7-9 and methoxide (10) derivatives (Scheme 1).
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Anticholinesterase activity results
Tacrine (THA, 1,2,3,4-tetrahydroacridine) is one of the most important inhibitor of both AChE and BChE enzymes. 4, 20, [32] [33] [34] Despite the lack of its selectivity and hepatotoxicity and limitation of its medical therapy, tacrine remains a reference compound (IC 50 = 59 nM for AChE and IC 50 = 23 nM for BChE, taken in our study) in the design and development of promising ChEs inhibitors candidates. The high AChE and BChE inhibitory feature of tacrine has encouraged us to development of the effective tacrine derivatives. activities, especially silyl and cyano substituted seven membered hydrocycle tacrines showed the highest AChE inhibitory activity compared with bromo tacrine analogues and galantamine. Also, these compounds showed to close to unsubstituted tacrine's inhibitory activity against AChE (Table 1) .
Carbonic anhydrases inhibition activity results
The disubstituted tacrine derivatives reported here were determined as inhibitors of two physiologically relevant CA isoforms, the cytosolic hCA I, hCA II by an esterase assay method. 35, 36 Acetazolamide (AZA), a clinically used sulfonamide CAI was used in the assays as a standard drug. The results are shown in Table 2 (IC 50 and K i values expressed as nanomolar (nM)). This study clearly indicated that disubstituted tacrine derivatives (1-3, 7-14) and its methyliodine salt form (6) showed good hCA I and hCA II inhibitory effects. The slow cytosolic isoform hCA I (take part in important physiological and pathological processes in many tissues and organs), was significantly inhibited by most of the disubstituted tacrine derivatives with K i s ranging between 43.81 and 471.67 nM. The best inhibitions for this isoform were determined by dibromo six membered 2 and dibromo seven membered 3 tacrine derivatives, with K i values of 111.76 and 43.81 nM, respectively. Additionally, acetazolamide (AZA) as sulphonamide compound was recorded for broad-specificity CA inhibitor which obtained K i value of 3320.46 nM against hCA I. CA II is often associated with several diseases such as glaucoma, osteoporosis and renal tubular acidosis. 37 For hCA II, disubstituted tacrine derivatives (1-3, 7-14) had K i values from 87.14 to 614.68 nM. Moreover, AZA (5-aceta-mido-1,3,4-thiadiazole-2-sulfonamide), which is used for the treatment of altitude sickness, cystinuria, idiopathic intracranial hypertension, glaucoma, epileptic seizure, dural estasia and central sleep apnoea, had a medium potency hCA II inhibition for this isoform, 38 with a K i value of 2718.92 nM. Also, dibromo six membered hydrocycle 2 and dibromo seven membered hydrocycle 3 tacrine derivatives have the highest inhibition effects against hCA II with K i values of 114.44 and 87.14 nM, respectively.
DISCUSSION
These compounds were defined in synthetically available position molecules of the aryl rings of tacrine analogues bearing six and seven membered hydrocycle as well as on primary amino group in order to evaluate the SAR mechanism of this series. The structural of disubstituted tacrine analogues of AChE and BChE enzymes inhibition data expressed as IC 50 values in nM level which are shown in Table 1 . Also hCA I and hCA II inhibitory potentials' data expressed as IC 50 and K i values in nM concentrations are shown in Table 2 .
It is evident that both nature and positions of the substituents at C-5 and C-7 for six membered hydrocycle tacrine and the substituents at C-6 and C-8 for seven membered hydrocycle tacrine analogues are able to vary the AChE and BChE inhibition activity of tacrine. However, we did not observe the variation and selectivity of hCA I and hCA II inhibitory potentials of disubstituted tacrine derivatives. 
CONCLUSION
In this work, disubstituted tacrine analogues, recently synthesized by our group, 18, 21 were found to be potent and selective inhibitors of AChE and BChE with IC 50 in nanomolar concentration scale. Moreover, we investigated and assessed as inhibitors of two physiologically related and important CA isoforms, the cytosolic, hCA I and hCA II. Then, we attempted to determine the SAR of the effects of the introduction of substituents in some position of tacrine. The substituted seven membered hydrocycle tacrine analogues selectively showed the effective inhibitory activity against AChE and BChE enzymes. The cyano at C-6 and C-8, silyl at C-6 and C-8 and thiomethyl at C-6 substituted seven membered hydrocycle tacrine derivatives (9, 11 and 14) have the good inhibitions against AChE (IC 50 in the range of 68-454 nM) while methoxy at C-6 substituted seven membered hydrocycle tacrine 10 showed the best inhibitory activity against BChE (IC 50 = 563 nM). All the disubstituted tacrine derivatives (1-3, 6-14) used in the present study described effective inhibition profiles against both hCA isoenzymes compared with acetazolamide (AZA), which used as a medication used to treat glaucoma, altitude sickness, epilepsy, idiopathic intracranial hypertension, periodic paralysis and heart failure. 39 In conclusion, disubstituted tacrine analogues, especially seven membered hydrocycle, have being a potential of cholinesterase enzymes inhibitor and both cytosolic CA isoenzymes. These results suggest that the dibromo tacrine derivatives may lead to synthesis of novel and effective CA inhibitors. In our ongoing research, we have been studing on cytotoxic profiles of substituted tacrine analogues in progress and we have obtained promising results. This present study and our ongoing research can contribute to the investigation of a cure for AD or therapy in the future.
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